Colon, Rectal, and Anal Cancer Management

Skibber, John M.; Eng, Cathy

doi:10.1007/0-387-31056-8_42

Cited by 3 publications

(7 citation statements)

References 329 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately half of treatment failures will be persistent and half recurrent. 6,27,31 Surgical salvage with radical resection, which prior to Nigro was the primary treatment for anal cancer, is now the standard of care for locoregional failure after CRT. 1,6,27,30,31 Outcomes for surgical salvage with abdominoperineal resection vary widely, with the 5-year survival rate ranging anywhere from 24 to 58%.…”

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

“…6,27,31 Surgical salvage with radical resection, which prior to Nigro was the primary treatment for anal cancer, is now the standard of care for locoregional failure after CRT. 1,6,27,30,31 Outcomes for surgical salvage with abdominoperineal resection vary widely, with the 5-year survival rate ranging anywhere from 24 to 58%. 1,27,[30][31][32] Proper patient selection for surgical salvage is imperative, and only half of patients who have locoregional failure will be candidates for abdominoperineal resection(APR).…”

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

“…Rates of wound complications with these techniques range from 0 to 100%. 6,27,31 In a study by Papaconstantinou et al, all patients undergoing flap reconstruction developed a wound complication; however, all of these occurred in patients with an extensive perineal resection, and all were able to be managed nonoperatively. 31 Figure 4 demonstrates a local recurrence of squamous cell carcinoma in a patient who had undergone rectus abdominis flap reconstruction of her perineal wound.…”

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

“…[2][3][4][5] It is 20 to 30 times less common than colon cancer with 3400 to 4000 cases diagnosed annually in the United States. 1,2,6 Historically, this had been a disease of older women, with onset in the 7 th decade of life, and a female to male predominance of up to 5 to 1. 2,7,8 However, with the onset of the HIV epidemic, there has been an increase in the number of younger men afflicted with anal squamous cell carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Epidermoid Cancers of the Anal Canal: Current Treatment

Blumetti

Bastawrous²

2009

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

Epidermoid carcinoma of the anal canal is an uncommon disease, but has increased in incidence with the HIV epidemic. Prior to the 1970s, treatment consisted of radical surgery with abdominoperineal resection. With the pioneering work of Dr. Norman Nigro, this has shifted to a nonsurgical approach, with primary treatment consisting of multimodality therapy with radiation and chemotherapy. This review provides an overview of the historical, current, and future treatments of epidermoid anal canal malignancies.

show abstract

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

Section: Complications Of Treatment and Newer Protocolsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Epidermoid Cancers of the Anal Canal: Current Treatment

Blumetti

Bastawrous²

2009

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

show abstract

“…The most common histological type is adenocarcinoma. Other rare variants of epithelial tumors include squamous cell carcinomas, adenosquamous carcinoma (adenoacanthoma), undifferentiated carcinomas, small cell, and neuroendocrine cancers 4 .…”

Section: Introductionmentioning

confidence: 99%

Rare Presentation of Rectal Carcinoma in a Yamani Patient

Aldhalee¹

2023

TUJNAS

View full text Add to dashboard Cite

show abstract

Prospects for Prostate Cancer Chemotherapy: Cytotoxic Evaluation and Mechanistic Insights of Quinolinequinones with ADME/PK Profile

Jannuzzi,

Yilmaz Goler,

Biswas

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The evaluation of in vitro biological activity of several previously reported quinolinequinones (AQQ1–5) against 60 human cancer cell lines (NCI-60) used by the National Cancer Institute’s Developmental Therapeutics Program (DTP) contributed to our earlier research on possible anticancer and/or antibacterial agents. Of interest, NCI-60 screening revealed that two quinolinequinones (AQQ1 and AQQ2) significantly reduced the proliferation of several cancer genotypes. Following the administration of a single dose and five additional doses, all quinolinequinones demonstrated a significant inhibitory effect on the growth of leukemia and other cancer cell lines. Hence, a series of subsequent in vitro biological assessments were performed to further understand the mechanistic impact of the compounds. In MTT assays, it was found that AQQ1 and AQQ2 exhibited higher efficacy against DU-145 cells (IC50 4.18 µM and 4.17 µM, respectively) compared to MDA-MB-231 (IC50 8.27 and 13.33 µM, respectively) and HCT-116 cells (IC50 5.83 and 9.18 µM, respectively). Additionally, AQQ1 demonstrated greater activity in this context. Further investigations revealed that AQQ1 inhibited DU-145 cell growth and migration dose-dependently. Remarkably, arrest of the DU-145 cell cycle at G0/G1 phase and ROS elevation were observed. Pharmacokinetic (PK) studies revealed that AQQ1 has better PK parameters than AQQ2 with %F of 9.83 in rat. Considering the data obtained with human liver microsomal stability studies, AQQ1 should have a better PK profile in human subjects. In silico studies (molecular dynamics) with three kinases (CDK2, CDK4, and MAPK) leading to cell cycle arrest at G0/G1 identified MAPK as a probable target for AQQ1. Taken together, our results showed that AQQ1 could be a potential chemotherapeutic lead molecule for prostate cancer.

show abstract

Colon, Rectal, and Anal Cancer Management

Cited by 3 publications

References 329 publications

Epidermoid Cancers of the Anal Canal: Current Treatment

Epidermoid Cancers of the Anal Canal: Current Treatment

Rare Presentation of Rectal Carcinoma in a Yamani Patient

Prospects for Prostate Cancer Chemotherapy: Cytotoxic Evaluation and Mechanistic Insights of Quinolinequinones with ADME/PK Profile

Contact Info

Product

Resources

About